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CD4+ T-cell infusion
CD8+ cytotoxic T cells from cancer patients can be expand-
ed in vitro, selected for antigen specificity, and then infused 
back to the patients to affect the tumor. This cytotoxic anti-
tumor effect depends directly on the action of CD4+ T cells. 
Previously this subset could not be isolated and expanded effi-
ciently; however, the identification of HLA class II–restricted 
tumor antigens such as NY-ESO-1 gave rise to methods for 
isolating and expanding CD4+ T cells. Hunder and colleagues 
then selected NY-ESO-1–specific CD4+ T cells from a meta-
static melanoma patient, expanded them in vitro, and infused 
them back into the patient. Evidence of cytokine release was 
observed, and the T-cell clones were present in the blood for 
at least 3 months. Amazingly, this infusion caused complete 
regression of the tumor, perhaps by stimulating the patient’s 
own T cells to respond to additional tumor antigens. This 
CD4+ T-cell isolation technique offers a very promising future 
for autologous cell infusion for treatment of malignant dis-
ease. (N Engl J Med 358:2698–703, 2008)
Early in the hair follicle
During homeostasis in the hair follicle (HF), stem cells (SCs) 
reside in a relatively quiescent state in the bulge and are 
periodically activated for postnatal hair development. The 
origin and organization of these cells within their niche have 
remained largely unknown. Nowak and colleagues recently 
discovered that SCs were specified during the earliest stages 
of HF morphogenesis. In addition, the transcription factor 
Sox9 is required for this specification and for maintaining 
the growth of HFs following initiation of morphogenesis. 
Using Sox9 as a marker, early bulge stem cells were traced 
to the hair placode, and Sox9-expressing cells were reported 
to contribute to all epithelial lineages. In cells lacking Sox9, 
HF and sebaceous gland morphogenesis was prohibited, and 
proper epidermal wound repair was inhibited. These studies 
lay the foundation for identification of new molecules and 
pathways that contribute to early SC formation. (Cell Stem 
Cell 3:33–43, 2008)
Stem cell induction from epithelial cells
Pluripotent embryonic stem (ES) cells have been induced 
from adult mouse and human fibroblasts via retroviral trans-
duction of transcription factors, including Oct3/4, Sox2, Klf4, 
and c-myc. These cells, termed induced pluripotent stem cells 
(iPS), exhibited characteristics of an undifferentiated state 
and may ultimately be used to produce patient-specific stem 
cells. Aoi and colleagues recently generated iPS from adult 
mouse primary hepatocytes and gastric epithelial cells via 
retroviral integration of the four transcription factors. These 
cells were identical to mouse ES cells in both morphology 
and proliferative ability. Furthermore, transplantation of these 
cells into nude mice resulted in tumors containing tissues of 
the three germ layers, including neural tissue and muscle, 
cartilage, and gut-like epithelial tissue, and indicating the 
pluripotency of these cells. Finally, this reprogramming did 
not require viral integration into specific genomic sites, sup-
porting the use of gene transfer methods that do not require 
an integration mechanism associated with tumorigenicity. 
(Science 321:699–702, 2008)
EB classification revisited
Epidermolysis bullosa (EB) was first described in 1886, and 
its first classification system was devised in 1962. Since then, 
transmission electron microscopy, immunofluorescence map-
ping, and mutational analysis have been employed to diag-
nose and classify the disorder. In 2007, the Third International 
Consensus Meeting on the Diagnosis and Classification of 
Epidermolysis Bullosa was held in Vienna, Austria, to dissect 
the current diagnostic system and to develop a strategy for 
clinical classification. The proposed revised classification 
system, which would be easily understood by clinicians, 
relies on clinical and nonmolecular laboratory findings. The 
categorization of EB into four major types and then into sub-
types was recommended. Mutational classification, although 
highly informative for basic researchers, was deemed unfea-
sible because of financial and accessibility difficulties for 
many patients. Ideally, this improved classification system 
will assist clinicians in the accurate diagnosis and treatment 
of EB patients. (J Am Acad Dermatol 58:931–50, 2008)
Smad2, skin tumor suppressor
Smad proteins, which are involved in transforming growth 
factor-β (TGF-β) signaling, are directly involved in growth 
inhibition and the epithelial–mesenchymal transition (EMT). 
Each of the Smad proteins (Smad2, -3, and -4), however, 
regulates genes involved in these processes differently. 
Hoot and colleagues examined the effects of keratinocyte-
specific Smad2 ablation in mice. Although these mice did 
not develop spontaneous tumors, the animals developed 
more tumors more quickly than wild-type controls fol-
lowing a two-step (7,12-dimethylbenz[a]anthracene and 
12-O-tetradecanoylphorbol-13-acetate) chemical carcino-
genesis protocol. These tumors were poorly differentiated 
and exhibited an increase in EMT. Loss of Smad2 was accom-
panied by molecular alterations of TGF-β target genes associ-
ated with EMT. Taken together, these results support a tumor 
suppressor role for Smad2. Interestingly, loss of heterozygos-
ity of Smad2 and Smad4 is frequently reported in human 
skin squamous cell carcinomas. Therefore, even the loss of 
one allele of Smad2 may result in a loss of tumor suppressor 
activity. (J Clin Invest 118:2722–32, 2008)
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